Whole-cell competition for androgen receptor binding
Cell-based study · LNCaP/AR(cs) prostate cancer cells with increased AR expression [1]
ARN-509 displaced 18F-FDHT in intact cells. Its apparent potency advantage over bicalutamide was assay-dependent: the authors report no corresponding separation in MDA-MB-453 cell extracts. This is a ligand-displacement IC50, not a treatment concentration or dissociation constant.
| Endpoint | Reported result | Reference |
|---|---|---|
| Displacement of 18F-FDHT from AR in whole cells | IC50 16.0 ± 2.1 nM (mean ± SEM, five replicate experiments) | [1] |
| Bicalutamide comparator in the same whole-cell binding assay | IC50 160 ± 29 nM (mean ± SEM, five replicate experiments) | [1] |
Literature-Reported Treatment Conditions
- Method
- Concentration-response competition against 18F-FDHT in intact LNCaP/AR(cs) cells.
- Reported limits
- Binding incubation time and vehicle are not specified in the read main-text methods/caption; detailed supplemental methods were not retrieved. No conditions were borrowed from another paper.
Methods and source locations
Compound reported in the paper: Apalutamide; Compound label in the paper: ARN-509
Reported research material and model only; no salt conversion or validation of a current Adooq lot.
Figure 1A–B and caption; Results, first AR-binding paragraph; Materials and Methods, ligand-binding studies
Displacement of 18F-FDHT from AR in whole cells: Whole-cell radioligand competition. Figure 1B representative curve uses n=3 with SD error bars; inset summarizes five replicate experiments. — Figure 1B inset and caption
Bicalutamide comparator in the same whole-cell binding assay: Same Figure 1B assay; FDHT and MDV3100 also included as competitors. — Figure 1B inset and caption